The peptide and oligonucleotide cdmo market size has grown rapidly in recent years. It will grow from $2.42 billion in 2025 to $2.7 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to growth in peptide-based therapeutics, increasing complexity of synthetic oligonucleotides, limited in-house manufacturing capabilities of drug developers, rising regulatory compliance requirements, early adoption of antisense and peptide drugs.
The peptide and oligonucleotide cdmo market size is expected to see rapid growth in the next few years. It will grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to expansion of oligonucleotide therapeutics pipelines, increasing investment in rare disease and oncology drugs, rising demand for rapid clinical trial material production, growing preference for specialized cdmo partnerships, advancements in solid-phase synthesis technologies. Major trends in the forecast period include rising outsourcing of peptide and oligonucleotide manufacturing, growing demand for cgmp-compliant complex molecule production, expansion of end-to-end development and manufacturing services, increased focus on high-potency and high-purity therapeutics, greater adoption of scalable and flexible manufacturing platforms.
The increasing uptake of personalized medicine is anticipated to fuel expansion in the peptide and oligonucleotide CDMO markets moving forward. Personalized medicine represents a healthcare strategy that customizes medical choices and therapies based on individual factors like genetics, environment, and lifestyle. This rising adoption stems from various drivers, including progress in genomic tools, deeper insights into molecular disease pathways, and the need for precise, effective treatments matched to patients' unique genetic backgrounds and health records. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are vital in this field, as they create bespoke therapeutic peptides and oligonucleotides suited to specific patient requirements. For example, in February 2024, the Personalized Medicine Coalition - a UK organization advocating for personalized medicine - noted that the FDA’s Center for Drug Evaluation and Research (CDER) greenlit 16 new personalized therapies for rare disease patients, compared to just 6 in 2022. Thus, the surge in personalized medicine is propelling the peptide and oligonucleotide CDMO market.
Major companies in the peptide and oligonucleotide CDMO market are prioritizing strategic partnerships to improve their service portfolios, bolster technological expertise, and broaden market presence. Peptide development and production partnerships involve collaborative deals between organizations aimed at creating and producing peptide-based therapies. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), teamed up with Numaferm GmbH, a Germany-based biotech firm, for peptide development and production. This alliance leverages PolyPeptide's cGMP manufacturing capabilities and market reach alongside Numaferm's skills in eco-friendly peptide manufacturing and biochemical platforms. The collaboration centers on co-developing promising peptide candidates to enable more sustainable production of peptide-based APIs.
In May 2024, EUROAPI, a France-based contract development and manufacturing organization, acquired BianoGMP for an undisclosed sum. The deal aimed to strengthen EUROAPI's standing in the contract development and manufacturing organization (CDMO) market for oligonucleotides, building on its existing capacity in Frankfurt. BianoGMP, a Germany-based contract development and manufacturing organization (CDMO), specializes in analytical services for oligonucleotides.
Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.
North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peptide and oligonucleotide cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the peptide and oligonucleotide CDMO market by increasing costs for imported raw materials, reagents, synthesis equipment, and specialized consumables used in manufacturing. These impacts are most pronounced in contract manufacturing services and therapeutic applications, particularly in regions dependent on cross-border chemical supply chains such as North America and Europe. Higher costs have pressured pricing and extended development timelines. However, tariffs have also encouraged localization of manufacturing, supplier diversification, and investments in domestic production capabilities.
The peptide and oligonucleotide cdmo market research report is one of a series of new reports that provides peptide and oligonucleotide cdmo market statistics, including peptide and oligonucleotide cdmo industry global market size, regional shares, competitors with a peptide and oligonucleotide cdmo market share, detailed peptide and oligonucleotide cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the peptide and oligonucleotide cdmo industry. This peptide and oligonucleotide cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A peptide and oligonucleotide CDMO (contract development and manufacturing organization) is a company offering services for the development, manufacturing, and supply of peptide- and oligonucleotide-based therapeutics. These organizations deliver specialized knowledge in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to enable production of peptides and oligonucleotides for diverse clients.
The primary product categories for peptide and oligonucleotide CDMOs consist of peptides and oligonucleotides. Peptides are brief sequences of amino acids, generally under 50 in length, which serve key functions in biological activities like signaling and hormone control. They offer services including contract development and contract manufacturing. These find use in areas such as therapeutics, research tools, diagnostics, and more, serving end-users like biopharmaceutical firms, pharmaceutical companies, research institutions, academic and government bodies, and others.
The peptide and oligonucleotide CDMO market consists of revenues earned by entities by providing services such as analytical testing, oligonucleotide synthesis services, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide and oligonucleotide CDMO market also includes sales of custom peptides and custom oligonucleotides. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The peptide and oligonucleotide cdmo market size is expected to see rapid growth in the next few years. It will grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to expansion of oligonucleotide therapeutics pipelines, increasing investment in rare disease and oncology drugs, rising demand for rapid clinical trial material production, growing preference for specialized cdmo partnerships, advancements in solid-phase synthesis technologies. Major trends in the forecast period include rising outsourcing of peptide and oligonucleotide manufacturing, growing demand for cgmp-compliant complex molecule production, expansion of end-to-end development and manufacturing services, increased focus on high-potency and high-purity therapeutics, greater adoption of scalable and flexible manufacturing platforms.
The increasing uptake of personalized medicine is anticipated to fuel expansion in the peptide and oligonucleotide CDMO markets moving forward. Personalized medicine represents a healthcare strategy that customizes medical choices and therapies based on individual factors like genetics, environment, and lifestyle. This rising adoption stems from various drivers, including progress in genomic tools, deeper insights into molecular disease pathways, and the need for precise, effective treatments matched to patients' unique genetic backgrounds and health records. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are vital in this field, as they create bespoke therapeutic peptides and oligonucleotides suited to specific patient requirements. For example, in February 2024, the Personalized Medicine Coalition - a UK organization advocating for personalized medicine - noted that the FDA’s Center for Drug Evaluation and Research (CDER) greenlit 16 new personalized therapies for rare disease patients, compared to just 6 in 2022. Thus, the surge in personalized medicine is propelling the peptide and oligonucleotide CDMO market.
Major companies in the peptide and oligonucleotide CDMO market are prioritizing strategic partnerships to improve their service portfolios, bolster technological expertise, and broaden market presence. Peptide development and production partnerships involve collaborative deals between organizations aimed at creating and producing peptide-based therapies. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), teamed up with Numaferm GmbH, a Germany-based biotech firm, for peptide development and production. This alliance leverages PolyPeptide's cGMP manufacturing capabilities and market reach alongside Numaferm's skills in eco-friendly peptide manufacturing and biochemical platforms. The collaboration centers on co-developing promising peptide candidates to enable more sustainable production of peptide-based APIs.
In May 2024, EUROAPI, a France-based contract development and manufacturing organization, acquired BianoGMP for an undisclosed sum. The deal aimed to strengthen EUROAPI's standing in the contract development and manufacturing organization (CDMO) market for oligonucleotides, building on its existing capacity in Frankfurt. BianoGMP, a Germany-based contract development and manufacturing organization (CDMO), specializes in analytical services for oligonucleotides.
Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.
North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peptide and oligonucleotide cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the peptide and oligonucleotide CDMO market by increasing costs for imported raw materials, reagents, synthesis equipment, and specialized consumables used in manufacturing. These impacts are most pronounced in contract manufacturing services and therapeutic applications, particularly in regions dependent on cross-border chemical supply chains such as North America and Europe. Higher costs have pressured pricing and extended development timelines. However, tariffs have also encouraged localization of manufacturing, supplier diversification, and investments in domestic production capabilities.
The peptide and oligonucleotide cdmo market research report is one of a series of new reports that provides peptide and oligonucleotide cdmo market statistics, including peptide and oligonucleotide cdmo industry global market size, regional shares, competitors with a peptide and oligonucleotide cdmo market share, detailed peptide and oligonucleotide cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the peptide and oligonucleotide cdmo industry. This peptide and oligonucleotide cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A peptide and oligonucleotide CDMO (contract development and manufacturing organization) is a company offering services for the development, manufacturing, and supply of peptide- and oligonucleotide-based therapeutics. These organizations deliver specialized knowledge in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to enable production of peptides and oligonucleotides for diverse clients.
The primary product categories for peptide and oligonucleotide CDMOs consist of peptides and oligonucleotides. Peptides are brief sequences of amino acids, generally under 50 in length, which serve key functions in biological activities like signaling and hormone control. They offer services including contract development and contract manufacturing. These find use in areas such as therapeutics, research tools, diagnostics, and more, serving end-users like biopharmaceutical firms, pharmaceutical companies, research institutions, academic and government bodies, and others.
The peptide and oligonucleotide CDMO market consists of revenues earned by entities by providing services such as analytical testing, oligonucleotide synthesis services, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide and oligonucleotide CDMO market also includes sales of custom peptides and custom oligonucleotides. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Peptide and Oligonucleotide CDMO Market Characteristics
3. Peptide and Oligonucleotide CDMO Market Supply Chain Analysis
4. Global Peptide and Oligonucleotide CDMO Market Trends and Strategies
5. Peptide and Oligonucleotide CDMO Market Analysis of End Use Industries
7. Global Peptide and Oligonucleotide CDMO Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Peptide and Oligonucleotide CDMO Total Addressable Market (TAM) Analysis for the Market
9. Peptide and Oligonucleotide CDMO Market Segmentation
10. Peptide and Oligonucleotide CDMO Market Regional and Country Analysis
11. Asia-Pacific Peptide and Oligonucleotide CDMO Market
12. China Peptide and Oligonucleotide CDMO Market
13. India Peptide and Oligonucleotide CDMO Market
14. Japan Peptide and Oligonucleotide CDMO Market
15. Australia Peptide and Oligonucleotide CDMO Market
16. Indonesia Peptide and Oligonucleotide CDMO Market
17. South Korea Peptide and Oligonucleotide CDMO Market
18. Taiwan Peptide and Oligonucleotide CDMO Market
19. South East Asia Peptide and Oligonucleotide CDMO Market
20. Western Europe Peptide and Oligonucleotide CDMO Market
21. UK Peptide and Oligonucleotide CDMO Market
22. Germany Peptide and Oligonucleotide CDMO Market
23. France Peptide and Oligonucleotide CDMO Market
24. Italy Peptide and Oligonucleotide CDMO Market
25. Spain Peptide and Oligonucleotide CDMO Market
26. Eastern Europe Peptide and Oligonucleotide CDMO Market
27. Russia Peptide and Oligonucleotide CDMO Market
28. North America Peptide and Oligonucleotide CDMO Market
29. USA Peptide and Oligonucleotide CDMO Market
30. Canada Peptide and Oligonucleotide CDMO Market
31. South America Peptide and Oligonucleotide CDMO Market
32. Brazil Peptide and Oligonucleotide CDMO Market
33. Middle East Peptide and Oligonucleotide CDMO Market
34. Africa Peptide and Oligonucleotide CDMO Market
36. Peptide and Oligonucleotide CDMO Market Competitive Landscape and Company Profiles
37. Peptide and Oligonucleotide CDMO Market Other Major and Innovative Companies
40. Peptide and Oligonucleotide CDMO Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Peptide And Oligonucleotide CDMO Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses peptide and oligonucleotide cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for peptide and oligonucleotide cdmo? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide and oligonucleotide cdmo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Peptides; Oligonucleotides2) By Service Type: Contract Development; Contract Manufacturing;
3) By Application: Therapeutics; Research Applications; Diagnostics; Other Applications
4) By End User: Biopharmaceutical Companies; Pharmaceutical Companies; Research Institutes; Academic and Government Organizations; Other End Users
Subsegments:
1) By Peptides: Active Pharmaceutical Ingredients (Apis); Peptide Drug Products; Peptide Synthesis And Manufacturing Services2) By Oligonucleotides: Antisense Oligonucleotides; Sirna And Mrna Oligonucleotides; Oligonucleotide Synthesis And Manufacturing Services
Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Ajinomoto Co. Inc.; Lonza Group Ag; Wuxi Apptec Co. Ltd.; Catalent Inc.; Piramal Pharma Ltd; Curia Global Inc.; Almac Group; Euroapi SA.; CordenPharma International; Bachem Holding AG; Genscript Biotech Corporation; PolyPeptide Group; Rentschler Biopharma SE; Ambiopharm Inc; ScinoPharm; Senn Chemicals AG; Aurigene Pharmaceutical Services; Creative Peptides; Sylentis S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Peptide and Oligonucleotide CDMO market report include:- Thermo Fisher Scientific Inc.
- Merck KGaA
- Ajinomoto Co. Inc.
- Lonza Group Ag
- Wuxi Apptec Co. Ltd.
- Catalent Inc.
- Piramal Pharma Ltd
- Curia Global Inc.
- Almac Group
- Euroapi SA.
- CordenPharma International
- Bachem Holding AG
- Genscript Biotech Corporation
- PolyPeptide Group
- Rentschler Biopharma SE
- Ambiopharm Inc
- ScinoPharm
- Senn Chemicals AG
- Aurigene Pharmaceutical Services
- Creative Peptides
- Sylentis S.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.7 Billion |
| Forecasted Market Value ( USD | $ 4.03 Billion |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
